Posted: 2017-11-03 in Press Releases
November 3, 2017 – Melbourne, Australia and Minnesota, United States – Osprey Medical (ASX:OSP) is pleased to share its high exposure presence and featured clinical experience with the DyeVert™ Plus System during the 29th annual TCT Conference held this past week in Denver, Colorado.
Presented at TCT’s CI-AKI: Preventive Measures That Work lunch symposium, three of the talks focused on the importance of contrast reduction as a component to reducing the risk of AKI in the cardiac catheterization lab. The key presentations included “The current state of CI-AKI in the cath lab” (Dr. Roxanne Mehran), “Effective methods for reducing contrast dosage to patients: The DyeVert Plus System”(Dr. Anand Prasad, M.D), and “Practical application for incorporating hydration and dye-saving protocol for patients at high risk for AKI” (Gautum Kumar M.D.).
Additionally, the CME (continuing medical education) accredited Hot Topic Session, Focus on Chronic Kidney Disease and Contrast Nephropathy, provided a comprehensive overview and prevention of AKI and managing special scenarios with patients at risk for AKI.
Osprey Medical featured its new tradeshow booth with its Be Kind to Kidney program highlighted to create awareness and education around the clinical society guidelines to Screen, Hydrate, and Reduce Contrast when treating high-risk patients.
Osprey Medical’s President and CEO, Mike McCormick, said: “This was a very successful TCT for Osprey Medical and provided us with high exposure to the physicians who are ultimately the end users of our one of a kind technology. We had very high booth traffic throughout the conference, particularly following the scientific presentations. Pleasingly, we are seeing growing awareness of the CI-AKI problem and physicians who visited our booth were looking for practical solutions to comply with clinical guidelines in treating high-risk patients in the cath lab.”